Exploring the potential of bioactive metabolites in COVID-19 management through main protease enzyme (M^PRO) inhibition

The COVID-19 pandemic has spurred global efforts to identify effective therapeutic strategies. One promising avenue involves exploration of bioactive metabolites as potential inhibitors of main protease enzyme (M^pro) of SARS-CoV-2 virus. M^pro plays a critical role in viral replication and is considered a prime target for drug development.This review delves in potential of bioactive metabolites in managing COVID-19 by inhibiting M^pro. Bioactive metabolites are naturally occurring compounds found in various organisms, including plants, fungi, and marine life, known for their diverse biological activities. They have shown promise in inhibiting enzymatic activity of M^pro, disrupt viral replication-mitigate infection. This study explores a wide range of bioactive, sources, and inhibitory effects on M^pro. It investigates mechanisms of action and binding affinities of these metabolites, shedding light on their potential as anti-COVID-19 agents. Moreover, the review discusses the development of bioactive metabolite-based drugs and their safety and efficacy in COVID-19 management. By elucidating the potential of metabolites in inhibiting M^pro, this review contributes to the development of novel therapeutic interventions for COVID-19, offering hope in the battle against ongoing pandemic. These findings may pave the way for development of effective treatments that can complement existing strategies in the fight against SARS-CoV-2.